Dow Jones
32.105,25 +75,14 (+0,23%) Nasdaq
11.787,40 +117,44 (+1,01%) Nikkei 225
27.419,61 -47,00 (-0,17%) EUR/USD
1,0840 -0,0025 (-0,2276%) BTC-EUR
25.997,29 +946,54 (+3,78%) CMC Crypto 200
616,80 +19,34 (+3,24%)
Royalty Pharma plc (RPRX)
Dopo ore:
| Chiusura precedente | 34,86 |
| Aperto | 35,00 |
| Denaro | 34,57 x 1000 |
| Lettera | 34,79 x 800 |
| Min-Max giorno | 34,58 - 35,13 |
| Intervallo di 52 settimane | 32,68 - 44,75 |
| Volume | |
| Media Volume | 1.833.538 |
| Capitalizzazione | 15,35B |
| Beta (5 anni mensile) | 0,39 |
| Rapporto PE (ttm) | 18,07 |
| EPS (ttm) | 1,93 |
| Prossima data utili | 03 mag 2023 - 08 mag 2023 |
| Rendimento e dividendo (forward) | 0,80 (2,10%) |
| Data ex dividendo | 15 feb 2023 |
| Stima target 1A | 53,71 |
- GlobeNewswire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTechTransaction provides further non-dilutive capital for PureTech’s growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023 NEW
- GlobeNewswire
Royalty Pharma Raises Full Year 2023 Guidance
Royalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA) approval of Zavzpret (zavegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spr
- GlobeNewswire
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley where he was a Managing Director and Head of West Coast Biotechnology Investment Banking. In his nearly two decade career, Ashwin has been involved in some o
